Product Information
ODEFSEY TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $130.4920 per EA under NDC 61958210101. Its NADAC has been published 537 times since Jun 22, 2016.
FDA first approved this application on Mar 1, 2016.
Strength
200; 25; 25 mg/1; mg/1; mg/1
Manufacturer
Gilead Sciences, Inc.NDC
61958210101
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATEApproval Type
New Drug (NDA)
FDA Application
NDA208351FDA Approved
3/1/2016
On Market Since
3/1/2016
Pharmacological Classes
Price Statistics
The NADAC for ODEFSEY TABLET has been published 537 times since Jun 22, 2016, and over the history we have for it it has risen 72.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $130.4920 per EA |
|---|---|
| All-time high | $130.4920 (Sep 30, 2026) |
| All-time low | $75.7630 (Jun 22, 2016) |
| 52-week high | $130.4920 |
| 52-week low | $124.2553 |
| Median price | $100.0229 |
| Average price | $102.0314 |
| Largest weekly change | +6.9% (Feb 15, 2017) |
| Weeks tracked | 537 |
| Tracking since | Jun 22, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Gilead Sciences, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ODEFSEY TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ODEFSEY TABLET, manufactured by Gilead Sciences, Inc., is $130.4920 per EA (NDC 61958210101), effective Sep 30, 2026.
How has the price of ODEFSEY TABLET changed over time?
Over the history we have for it, the NADAC for ODEFSEY TABLET has risen 72.2%. It has been tracked across 537 weekly CMS publications since Jun 22, 2016.
What are the highest and lowest recorded NADAC prices for ODEFSEY TABLET?
Since Jun 22, 2016, the NADAC for ODEFSEY TABLET has ranged from a low of $75.7630 (Jun 22, 2016) to a high of $130.4920 (Sep 30, 2026), with a median of $100.0229 per EA.
Are there cheaper alternatives to ODEFSEY TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ODEFSEY TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ODEFSEY TABLET?
ODEFSEY TABLET (NDC 61958210101) is labeled by Gilead Sciences, Inc., and CMS classifies it as a brand product.